SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC jumps after reporting positive top-line results for investigational drug ‘SDN-037’

14 Oct 2020 Evaluate

Sun Pharma Advanced Research Company is currently trading at Rs. 170.35, up by 1.00 points or 0.59% from its previous closing of Rs. 169.35 on the BSE.

The scrip opened at Rs. 173.00 and has touched a high and low of Rs. 173.00 and Rs. 169.55 respectively. So far 14838 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 210.70 on 28-Jan-2020 and a 52 week low of Rs. 81.00 on 25-Mar-2020.

Last one week high and low of the scrip stood at Rs. 177.75 and Rs. 167.50 respectively. The current market cap of the company is Rs. 4471.84 crore.

The promoters holding in the company stood at 68.46%, while Institutions and Non-Institutions held 3.11% and 28.43% respectively.

Sun Pharma Advanced Research Company (SPARC) has reported positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery. The trial met its pre-specified primary and secondary objectives, demonstrating that SDN-037 is superior to its vehicle.

The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain. To that end, the primary efficacy measure was the proportion of subjects with an anterior chamber cell (ACC) grade of zero on Day 15 (zero inflammation). A statistically significant proportion of patients treated with SDN-037 achieved an ACC grade of 0 versus vehicle with p-values <0.0001 in the Intent-To-Treat population.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×